Skip to main content

Table 1 Baseline characteristics of the 1003 AS patients and 1747 RA patients who were working at baseline

From: Fatigue independently predicts different work disability dimensions in etanercept-treated rheumatoid arthritis and ankylosing spondylitis patients

Parameter AS n RA n
Age (years), mean (SD) 40.7 (10.6) 1003 47.3 (9.9) 1747
Female, % 36.7 1003 72.4 1747
Disease duration (years), mean (SD) 7.3 (7.8) 979 7.9 (7.6) 1654
Disease activity 0–10 Likert, mean (SD) 6.3 (1.7) 1000  
0–100 mm VAS, mean (SD)   59.1 (18.0) 1724
CRP (mg/dL), median (min, max) 1.0 (0.0, 42.7) 906 0.9 (0.0, 20.0) 1534
Fatigue 0–10 cm VAS, mean (SD) 5.6 (2.4) 997  
0–100 mm VAS, mean (SD)   57.4 (24.9) 1735
Pain 0–10 Likert, mean (SD) 6.3 (2.2) 990  
0–100 mm VAS, mean (SD)   61.6 (21.4) 1736
Anxiety/depression
(EQ-5D)
No problems, % 53.6 998 52.1 1738
Some problems, % 42.7 44.4
Extreme problems, % 3.7 3.6
WPAI:SHP
% work time missed due to AS/RAa No timed missed 61.9 776 61.3 1293
Some time missed 38.1 38.7
% impairment while working due to AS/RAb, mean (SD) 48.3 (26.9) 889 49.5 (27.1) 1530
% overall work impairment due to AS/RAc, mean (SD) 52.9 (29.8) 716 54.1 (29.0) 1171
% activity impairment due to AS/RAd, mean (SD) 53.4 (24.6) 990 54.0 (24.9) 1718
  1. aAbsenteeism
  2. bPresenteeism
  3. cWork productivity loss
  4. dActivity impairment
  5. AS, ankylosing spondylitis; CRP, C-reactive protein; EQ-5D, European Quality of Life 5 Dimensions; RA, rheumatoid arthritis; SD, standard deviation; VAS, visual analogue scale; WPAI:SHP, Work Productivity and Activity Impairment—Special Health Problems